BioSpace News Archive

To Enhance Its Existing Intellectual Property Portfolio, the Company Filed an Additional U.S. Provisional Patent Application Directed to: Alternative Pharmaceutical Cannabinoid Delivery Systems

Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced the closing of its merger with Neos Therapeutics.

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced that it will release its financial results for fiscal year 2020 and business update on Tuesday, March 30, 2021.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it has retained Summit Biosciences, a world-wide leader in nasal spray pharmaceuticals, to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate.

Oncology research pioneer Anchiano was one of the best performers in the biotech space during Mr. Polovets’ one-year tenure.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has acted on a request to provide opaganib[1] treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

PYC Therapeutics, a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, announced it was invited to participate as one of a select group of companies at the SVB Leerink Biopharma Private Company Connect, taking place virtually on March 25-26, 2021.

Collaboration to focus on the continued development of chronic heart failure treatment SERCA2a activator compounds adding to Windtree’s acute treatment Istaroxime

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH)

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, and Humana, a leading national consumer-focused, technology-driven health plan known for its commitment to innovation, announced the expansion of their collaboration in a focus on vaccine adherence.